

Docket No. 1151-4153US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

WANG et al

Group Art Unit: TBA

Serial No

09/701,623

Examiner: TBA

Int. Filing Date:

June 21, 1999

For

PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT

OF ALLERGY

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 USC 371

Commissioner for Patents

Box PCT

Washington, DC. 20231

Sir:

In response to the Notification of Missing Requirements under 35 U.S.C. 371 dated April 2, 2001, and Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures copies of which are enclosed, please find a computer readable form of the Sequence Listing (disc) and a paper copy of the Sequence Listing. In addition, enclosed is a Statement Under 37 C.F.R. 1.821(f). It is believed that no fees are required in connection with this response, however, if any fees are due the Commissioner is authorized to charge any such fees to Deposit Account No. 13-4500, Order No. 1151-4153US1. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: May 1, 2001

Maria C.H. Lin

Registration No. 29,323

CORRESPONDENCE ADDRESS: MORGAN & FINNEGAN LLP 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

S	ON DESCRIPTION OF THE PROPERTY			13D 12TO T		Commissio United States Pate	oner for Patents, B ent and Trademark Washington, D.C	COffice
100	09/701,623	₩Д	NG	12.81 t. 				uspto.gov
	U.S. APPLICATION NO.	12 (1751		MED APPLICANT		- ATTY, D	OCKET-NO 1	J - 0000.
		AUUL A	2H -5	A II: 52				ר
	MORGAN & FINNLGAN			5611	<u></u>	NTERNATIONAL APPLICAT	<u>PS99/139</u> 5	3 9
.	345 PARK AVENUE	#1 G	13 Fimi	EGAN LLP			ė	
	NEW YORK NY 10154-	0053	•				PRIORITY DATE	٦
					I.A. FI	TLING DATE 06/21/95		/20/98
			• :					
					1		04/02/01	1 .
						ATE MAILED:		
. '	NOTIFICATION OF MISSIN	G REQU	IREME	NTS UNDE	R 35 U.S.	C. 371 IN THE	E UNITED	
	STATES DES	SIGNATI	ED/ELE	CTED OF	JCR (DO)	EO/US)		
	1. The following items have been submit	ted by the a	pplicant or	the IB to the	United States	Patent and Tradema	ark	
	Office as a Designated Office	(37 CFR 1.	494) 🔀	an Elected Off	10e (3/ CFK	1.495):		
	U.S. Basic National Fee.	t' a!	Indica	tion of Small I	enuty Status. ternational an	plication into Engli	sh.	
	Copy of the international app Oath or Declaration of invent	ncauon.	Trans	lation of Articl	e 19 amendm	ents into English.		
	- C f A miela 10 amendme	nts.	Other					
	Priority Document.		_					
	The International Preliminary	/ Examination	n Report	n English and	its Annexes,	if any.	•	
	Translation of Annexes to the	e Internation	al Prelimi	ary Examinati	on Report int	o English.		
	, -	d	25 11 9 0	371(f) but ha	s not filed the	following indicates	d items and/or	
	2. Applicant has requested early proce the indicated items in paragraph 3 below.	ssing under	33 U.S.C National F	ee and the con	v of the intern	national application	must be filed	
	prior to 20 or 30 months from the priority	date to avo	id abandor	ment.		•		
	U.S. Basic National Fee.		Сору	of the internat	ional applicati	ion.	•	
				et forth helow	in order to co	amplete the requirer	nents for	•
٠.	3. The following items MUST be furnish acceptance under 35 U.S.C. 371:						LOUID TO	
	a. Translation of the applicat	ion into Eng	dish. A pı	ocessing fee w	ill be require	d if submitted		•
	later than the appropria	te 20 or 30	months fro	m the priority	date.			
	The current translation	is defective	for the rea	sons indicated	on the attache	ed Notice of Defect	ive.	
	Translation. b. Processing fee for providi	no the trans	lation of th	e application a	nd/or the An	nexes later than the		
	appropriate 20 or 30 m	onths from	the priority	date (37 CFR	1.492(f)).	•		•
	C Oath or declaration of the	inventors, i	n compliar	ice with 37 CF	R 1.497(a) ar	nd (b), properly ide	ntifying	
	the application (prefera	bly by the I	nternationa	l application n	umber and int	ternational filing da	ite). A	
•	surcharge will be requi	red if submi	tted later t	nan the approp	mate 20 or 30	monus from the p	niority	
	date. The current oath or dec	laration doe	s not com	oly with 37 CF	R 1.497(a) an	nd (b) for the reason	as	-
	indicated on the attache	A PCT/DO	EO/917.					
	d. Surcharge for providing the		eclaration	later than the a	ppropriate 20	or 30 months from	i the	
1	priority date (37 CFR 1 4. Additional claim fees of \$	1.492(e)).	large entity	small enti	ty, including	any required multip	ple dependent	
: ;	claim fee, are required. Applicant must	submit the a	dditional c	Laim fees or ca	ncel the addit	tional claims for wh	nich fees are	
	due (37 CFR 1.492(g)). See attached PT	O-875.			` \ \		•	
., :	5. Applicant has not submitted the rec		nce listing	nursuant to 37	CFR 1.821-	1.825. See attache	ed .	
1	PCT/DO/EO/920.	datter sedar	нос пость	purounii io o				
٠.	ALL OF THE ITEMS SET FORTH IN MONTHS FROM THE DATE OF TH	V 3(a)-3(d),	4 AND 5	ABOVE MUS	T BE SUBM	ITTED WITHIN	TWO (2) polies) FROM	
	THE PRIORITY DATE FOR THE AP	PLICATIO	N. WHIC	HEVER IS L	ATER. FAI	LURE TO PROP	ERLY	
٠.	RESPOND WILL RESULT IN ABAN	DONMENT	·					
	The time period set above may be extend			and fee for ext	ension of time	e under the provision	ons of 37 CFR	
Ċ,	The time period set above may be extend 1.136(a).	ied by ming	a pennon	and lot for CA	CHISTON OF CHIS	o ancor are provide		
								1 1
	6. If box 3a or 3c is checked, a translation. Annexes will be cancelled: A processing	on of the A	nexes MU	ST be submitted late	ed no later that or than 20 or	an the time period s 30 months from the	e priority date.	1 7
	7 The Article 19 amendments are ca	ncelled sinc	e a translat	ion was not pr	ovided by the	appropriate 20 (37	CFR 1.494(d)	1 3
	or 30 (37 CFR 1.495(d)) months from th	e priority d	ite.			•		Y
	A SERVICE OF THE SERV		*	D and	Tandamark (Office must be mail	~	08
	Applicant is reminded that any communic address given in the heading and include	cation to the	nlication n	o, shown abov	e. (37 CFR 1	.5)	* 1 3	8 ~
. `.		er i Salar i Salar	aran e .			*	17.7	四四
اعترف ف	A copy of this	s notice .	MUST I	be returned	d with this	s response.	31,8	多心
	Enclosed: PCT/DO/EO/917			ctive Translati	on '	9900分裂が170mm 構成の製作した。	(a) 3	
. i	P10-875	⊳ ⊠ PC	r/doæo/	720	Shakeel A	Ahm d	多多	E I
	FORM PCT/DO/EO/905 (March 2001)	100		Telepho	one: 703-30		717	UTORY DAT
	FORM FOT INDOPEDITION (MINICIN 2001)	: • •				J-0000	12	≥ 6
					· · · · · · · · · · · · · · · · · · ·			6
	1. P						CASE DUE DA	5
			1	•			SI	Ħ
	And the second second		eries (1964) Parties (1964)				CASI	<u> </u>
		ئىيىن ئىسىدىن ئارى	。() 《 ·西	10 10 18 T	 ·	-	0	. حنت سه

UNITED STATES PATE			Commissioner for Patents, Boi United States Patent and Trademark (Washington, D.C. www.us	Office 20231
LS. APPLICATION NO.1 . (23	WF	NEED APPLICANT	C ATTY, DOCKET NG 151	4153l
			<u>.</u>	
	•	5611	INTERNATIONAL APPLICATION NO.	rin ara
MORGAN & FIN		1	PCT/US99/139	57
345 PARK AVE		· 1		
NEW YORK NY	10(54-0053	} [I.A. FILING DATE PRIORITY DATE	
	•	1	06/21/99	6/20.
		-	04/02/0	i
			DATE MAILED:	
			FOR PATENT APPLICATIONS	
policant has submitted p	aners under 35 U.S	S.C. 371 to enter the	national stage in the United States of	
merica. The items indic	apers under 35 U.S	S.C. 371 to enter the page 7. are missing. The	national stage in the United States of period within which to correct the accompanying Notification.	
merica. The items indic ficiency noted below an	apers under 35 U.S ated below, howeved avoid abandonm	S.C. 371 to enter the ver, are missing. The ent is set forth in the a	period within which to correct the accompanying Notification.	
nerica. The items indic ficiency noted below an	apers under 35 U.S ated below, howeved d avoid abandonm	S.C. 371 to enter the party of the sent is set forth in the addisclosure contained in	period within which to correct the accompanying Notification. In this application does not comply	
nerica. The items indic ficiency noted below an ne nucleotide and/or ami th the requirements for	apers under 35 U.S ated below, howeved d avoid abandonm	S.C. 371 to enter the party of the sent is set forth in the addisclosure contained in	period within which to correct the accompanying Notification.	
nerica. The items indic ficiency noted below an ne nucleotide and/or ami th the requirements for	apers under 35 U.S ated below, howeved d avoid abandonm	S.C. 371 to enter the party of the sent is set forth in the addisclosure contained in	period within which to correct the accompanying Notification. In this application does not comply	
nerica. The items indic ficiency noted below an ite nucleotide and/or ami th the requirements for ason(s):	apers under 35 U.3 ated below, however d avoid abandonm ino acid sequence of such a disclosure a	S.C. 371 to enter the rever, are missing. The ent is set forth in the addisclosure contained in as set forth in 37 CFR	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following	
nerica. The items indic ficiency noted below an e nucleotide and/or ami th the requirements for ason(s):	apers under 35 U.S ated below, howeved d avoid abandonm ino acid sequence of such a disclosure a a fails to comply we	S.C. 371 to enter the aver, are missing. The ent is set forth in the addisclosure contained in as set forth in 37 CFR with the requirements of	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825.	
nerica. The items indic ficiency noted below an ite nucleotide and/or amin the the requirements for ason(s): The application This application	apers under 35 U.s ated below, however d avoid abandonm ino acid sequence of such a disclosure a in fails to comply win does not contain	S.C. 371 to enter the rever, are missing. The ent is set forth in the addisclosure contained in as set forth in 37 CFR with the requirements of a "Sequence Listing".	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825. The accompanying Notification is a separate part of the	
nerica. The items indic ficiency noted below an e nucleotide and/or ami th the requirements for ason(s): The application This application disclosure on	apers under 35 U.3 ated below, however d avoid abandonm ino acid sequence of such a disclosure a in fails to comply we in does not contain	S.C. 371 to enter the party of the control of the c	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825. The as a separate part of the by 37 CFR 1.821(c).	
nerica. The items indiction incidency noted below and the nucleotide and/or amight the requirements for uson(s): The application of the disclosure on the copy of the	apers under 35 U.3 ated below, however d avoid abandonme ino acid sequence of such a disclosure a in fails to comply we in does not contain paper copy or com "Sequence Listing"	S.C. 371 to enter the party of the control of the c	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825. The accompanying Notification is a separate part of the	
nerica. The items indic ficiency noted below an ite nucleotide and/or ami th the requirements for ason(s): The application This application disclosure on A copy of the	apers under 35 U.3 ated below, however d avoid abandonme ino acid sequence of such a disclosure a in fails to comply we in does not contain paper copy or com "Sequence Listing CFR 1.821(e).	S.C. 371 to enter the average are missing. The ent is set forth in the addisclosure contained in as set forth in 37 CFR with the requirements of a "Sequence Listing spact disc, as required" in computer readable.	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825. The as a separate part of the by 37 CFR 1.821(c). The format has not been submitted as	
merica. The items indice ficiency noted below and the nucleotide and/or amight the requirements for ason(s): The application of the copy of the required by 37 A copy of the	apers under 35 U.3 ated below, however d avoid abandonme ino acid sequence of such a disclosure a in fails to comply we in does not contain paper copy or com "Sequence Listing CFR 1.821(e). "Sequence Listing	S.C. 371 to enter the average of the second	period within which to correct the accompanying Notification. In this application does not comply 1.821-1.825 for the following of 37 CFR 1.821-1.825. The as a separate part of the by 37 CFR 1.821(c).	

Sequence Listing.' The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:

APPLICANT MUST PROVIDE: An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL

(703) 308-4216, for Rules interpretation,

(703) 308-4212, for CRF submission help,

(703) 287-0200, for PatentIn software help.